SAN DIEGO, March 8 Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use diagnostic system for measuring platelet reactivity to multiple antiplatelet agents (e.g. Plavix® and aspirin), announced today that the company will host an industry-expert theater presentation on Monday, March 15, during the 59th annual American College of Cardiology Meeting.
Advertisement
The ACC industry-expert theater presentation will focus on a rapidly evolving and exciting topic: assessing patient response to antiplatelet therapies and the impact on clinical outcomes. The hour-long panelist session will take place from 9:30 - 10:30 a.m. in Hall B4 in the ACC Expo Hall, Georgia World Conference Center. More information on the industry-expert theater presentation can be found at http://www.accumetrics.com/program/.
Advertisement
The impact of antiplatelet reactivity testing was recently highlighted in the POPular Study as a Late Breaking Clinical Trials session at the American Heart Association's Annual Scientific Sessions (the POPular data was formally published in the February 2010 issue of JAMA).
Researchers presented the first head-to-head comparison of multiple antiplatelet function tests in predicting adverse events in patients undergoing elective coronary stenting; data encouraged investigators to note that platelet reactivity testing may soon become a routine clinical tool.
"Accumetrics continues to be very encouraged by the increasing data highlighting the clinical utility of assessing response to antiplatelet therapies and the power of the data supporting VerifyNow," stated Timothy I. Still, president and CEO of Accumetrics.
Accumetrics will also host booth #2531 during the entirety of the conference.
About Accumetrics
Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.
Accumetrics' VerifyNow System is the first rapid and easy to use platform to help physicians determine an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient®) and clopidogrel (Plavix)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions. For more information about the Company and its products, visit www.accumetrics.com.
The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of sanofi-aventis. Effient is a registered trademark of Eli Lilly and Company.
CONTACT: Megan Rusnack Lippert/Heilshorn & Associates 212-838-3777 [email protected] Timothy I. Still President and CEO Accumetrics 858-404-8260 [email protected]
SOURCE Accumetrics, Inc.
